Hyperuricemia in children and adolescents with autism spectrum disorders treated with risperidone: The risk factors for metabolic adverse effect

Abstract

Introduction The prevalence of hyperuricemia in ASDs pediatric patients including the association of serum uric acid and metabolic adverse effect in ASDs pediatric patients treated with risperidone have never been examined. Objective To determine the prevalence of hyperuricemia in ASD pediatric patients treated with risperidone and the relationships between serum uric acid level and risk factor components of metabolic syndrome. Methods This cross-sectional study recruited 127 Thai ASDs children and adolescents, which age 3–20 years and had received risperidone for more than 4 weeks. The condition of hyperuricemia was defined as a high level of uric acid in the blood>5.5mg/dL. Results Hyperuricemia was observed in 73 of 127 (57.48%) subjects. Serum uric acid level were statistically significant positively associated with age, risperidone dose, duration of treatment, BMI, waist circumference, triglycerides (TG), TG/HDL cholesterol ratio, insulin, homeostatic model assessment index (HOMA-IR), leptin, and high-sensitivity CRP (hs-CRP). Furthermore, serum uric acid was statistically significant negatively associated with HDL cholesterol and adiponectin level. In multiple regression, only age, BMI, TG/HDL-C, and adiponectin level remained significant associated with serum uric acid level ( P Conclusions High level of serum uric acid related with adolescence. Serum uric acid level correlated with most of the risk factors of metabolic syndrome, except blood glucose and LDL-C levels. The information might encourage the clinicians for aware to the possible consequences of hyperuricemia, in order to verify possible complications of early metabolic syndrome in ASDs pediatric treated with risperidone.